founded in 2007, celyad is a clinical-stage biopharmaceutical company that leverages unique know-how in taking cell-based therapies from bench to phase iii, as well as the manufacturing and logistical infrastructure for such complex products. celyad builds it business model on partnering with prominent research institutions such as dartmouth college, and develops those programs from bench to commercial applications. the company is currently developing clinical programs in immuno-oncology, testing natural killer receptors t-cells (nkr-t cells) for cancer treatment. a unique approach that has the potential to target and destroy a vast majority of tumor types. celyad is listed on euronext brussels, euronext paris and on nasdaq (cyad).
Company profile
Ticker
CLYYF, CLYYF
Exchange
Website
CEO
Filippo Petti
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CARDIO3 BIOSCIENCES S.A., CELYAD S.A.
SEC CIK
CLYYF stock data
Latest filings (excl ownership)
15F-12B
Securities registration termination (foreign)
9 Feb 24
6-K
Celyad Oncology provides fourth quarter 2023 business update and 2024 outlook
17 Jan 24
6-K
Publication of a transparency notification received from Fortress Investment Group LLC
21 Dec 23
6-K
Current report (foreign)
18 Dec 23
6-K
Celyad announces management change
4 Dec 23
6-K
Current report (foreign)
4 Dec 23
6-K
Celyad Oncology reports third quarter 2023 financial
24 Nov 23
6-K
Publication of a transparency notification received from
21 Nov 23
6-K
Current report (foreign)
21 Nov 23
6-K
Information on the Total Number of Voting Rights and Total Number of shares with single voting rights
15 Nov 23
Latest ownership filings
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
0.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 1 |
Closed positions | 3 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 3.60 mm |
Total shares | 9.00 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Rhumbline Advisers | 9.00 k | $3.60 mm |